-
In Hollywood, AI's no match for creativity, say top executives
-
Sao Paulo AI policing nabs criminals, and a few innocents
-
Trump faces coalition of the unwilling on Iran
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
Former tennis world number 39 banned for doping
-
Kennedy Center board approves 2-year closure for renovation
-
US judge halts implementation of Trump vaccine overhaul
-
Afghanistan accuses Pakistan of deadly airstrike on drug rehab centre in Kabul
-
Iran footballers train with Australia club and say 'everything will be fine'
-
Trump asks China to delay Xi summit as Iran war rages
-
Multiple suicide bombers hit Nigeria's Maiduguri city after years of calm
-
Wolves fightback frustrates Brentford
-
Israel president says Europe should back fight against Hezbollah as troops operate in Lebanon
-
Israel president tells AFP Europe should back efforts to 'eradicate' Hezbollah
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Mbappe set for Real Madrid return against Man City
-
Nvidia rides 'claw' craze with AI agent platform
-
Alleged narco trafficker makes first US court appearance
-
Neymar misses out as Endrick returns to Brazil squad
-
Afghanistan accuses Pakistan of killing civilians in Kabul strike
-
South Lebanon's Christian towns insist they are not part of Israel-Hezbollah war
-
Alleged narco trafficker Marset makes first US court appearance
-
Securing the Strait of Hormuz: Tactics and threats
-
Cuba hit by total blackout as US fuel blockade bites
-
'Buffy' reboot cancelled: Sarah Michelle Gellar
-
PSG will go for the kill against Chelsea: Dembele
-
Afghan govt accuses Pakistan after new strikes on Kabul
-
Chelsea huddle not meant to 'antagonise' says Rosenior
-
Talks towards international panel to tackle 'inequality emergency' begin at UN
-
Trump pushes for 'enthusiasm' from allies to secure Hormuz
-
US, China hold 'constructive' talks on trade, but Trump visit in doubt
-
Laporta's new Barca chapter begins with Newcastle clash
-
EU talks energy as oil price soars
-
Out-of-favour Livingstone says 'no-one cares' in England set-up
-
Rising star Antonelli says Chinese GP triumph 'starting point' for F1 success
-
Stagflation risk in US 'quite high': Nobel-winning economist Stiglitz
-
Israel army says ground assault against Hezbollah underway in Lebanon
-
Swiss government rejects proposal to limit immigration
-
Ingredients of life discovered in Ryugu asteroid samples
-
Why Iranian drones are hard to stop
-
Teen star Dowman ready to make impact for Arsenal says Arteta
-
Jones says England would be 'foolhardy' to sack Borthwick before Rugby World Cup
-
Man City must be 'perfect' to stun Real Madrid: Guardiola
-
Ntamack set for Toulouse return at Bordeaux-Begles
-
Hours-long fuel queues in Laos capital Vientiane
-
France threatens to block funds for India over climate inaction
-
Will Yemen's Houthis join the Mideast war?
-
Oscar winner Sean Penn skips ceremony to visit Kyiv
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
J.Sauter--VB